Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Daiichi Sankyo Ltd ADR (OP:DSNKY)

26.96 +0.29 (+1.09%)
Streaming Delayed Price Updated: 3:14 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Daiichi Sankyo Ltd ADR

< Previous 1 2 3 Next >
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due. 
Via Benzinga
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast cancer in a Phase 3 trial, showing promising early results. 
Via Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024
Daiichi Sankyo Co just reported results for the first quarter of 2024. 
Via InvestorPlace
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
 
Via Benzinga
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial. 
Via Benzinga
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase 3 trial data. 
Via Benzinga
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients. 
Via Benzinga
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free... 
Via Benzinga
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... 
Via Benzinga
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to... 
Via Benzinga
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant? 
Via MarketBeat
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
"As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say. 
Via Benzinga
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises... 
Via Benzinga
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
Undervalued Nasdaq 100 stocks may not be as rare as hen's teeth but not quite so plentiful amid a raging bull market. 
Via InvestorPlace
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The... 
Via Benzinga
Why Is AstraZeneca Stock Trading Lower On Tuesday?
AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance. 
Via Benzinga
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023
Daiichi Sankyo Co just reported results for the third quarter of 2023. 
Via InvestorPlace
Double Good News For AstraZeneca's Breast Cancer Drugs
Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer. 
Via Benzinga
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal... 
Via Benzinga
What's Going On With Pfizer Stock Today?
Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues. 
Via Benzinga
Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares are trading lower on Wednesday after the company announced a $125 million amendment to the collaboration with Japanese pharma company Daiichi Sankyo... 
Via Benzinga
Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
Japanese stocks are gaining favor among I-banks and sport attractive valuations; here are 3 stocks with low P/B that have outperformed and could generate shareholder wealth. 
Via Benzinga
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
In due time, its new partnership with Daiichi Sankyo could be massive. 
Via The Motley Fool
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:  
Via Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria 
Via Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in 
Via Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung... 
Via Benzinga
Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
Australia biotech startup Psylo has inked a sponsored research agreement with global Japanese pharmaceutical company Daiichi Sankyo (OTCMKTS: DSNKY) toward advancing antidepressant psychiatric... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.